ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sotatercept

Also written as “Sotatercept”, “Sotatercept 0.3 mg/kg” and “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”.

Its studies are mostly in Pulmonary Arterial Hypertension · Anemia · Hypertension, Pulmonary · Multiple Myeloma · beta-Thalassemia, led by 2 companies.

Drug pageSotatercept: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 15, 202626 company-led studies, 8 open or runningNext primary completion: Mar 21, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck228 open or runningphase 4since May 15, 2026May 22, 2009Mar 21, 2028phase 4 · NCT07899905
Bristol-Myers Squibbits history only40 open or runningphase 2since Sep 3, 2008Sep 3, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since May 22, 2009.

  1. May 13, 2021Phase 3 study in Pulmonary Arterial HypertensionNCT04896008 · 173 enrolled · United States, Australia, Belgium and more
  2. Jun 11, 2021Phase 2 study in Hypertension, PulmonaryNCT04945460 · 165 enrolled · United States, Belgium, Canada and more
  3. Oct 17, 2022Phase 2 study in Pulmonary Arterial HypertensionNCT05587712 · 42 planned · United States, Australia, Colombia and more
  4. Apr 5, 2023Phase 3 study in Pulmonary Arterial HypertensionNCT05818137 · 46 enrolled · Japan
  5. Oct 28, 2024Phase 2 study in Pulmonary Arterial HypertensionNCT06664801 · 164 enrolled · United States, Argentina, Australia and more
  6. Feb 3, 2025Phase 2 study in Hypertension, PulmonaryNCT06814145 · 440 enrolled · United States, Belgium, Canada and more
  7. Feb 20, 2025Phase 1 study in HealthyNCT06843460 · 24 enrolled · China
  8. Apr 7, 2025Phase 2 study in Pulmonary Arterial HypertensionNCT06925750 · 130 enrolled · United States, Argentina, Australia and more
  9. Apr 9, 2025Phase 1 study in HealthyNCT06930664 · 146 enrolled · United States
  10. Oct 7, 2025Phase 3 study in Pulmonary Arterial HypertensionNCT07218029 · 815 enrolled · United States, Argentina, Australia and more
  11. May 15, 2026Phase 4 study in Pulmonary Arterial HypertensionNCT07600723 · 30 planned · India
  12. Jun 9, 2026Phase 2 study in Pulmonary Arterial HypertensionNCT07646860 · 6 planned · Japan
  13. Sep 18, 2026Phase 3 study in Hypertension, PulmonaryNCT07839585 · 352 planned
  14. Oct 21, 2026Phase 4 study in Hypertension, PulmonaryNCT07899905 · 40 planned

Ahead

  1. Mar 21, 2028Primary completion: phase 4 study in Hypertension, PulmonaryNCT07899905
  2. Apr 3, 2028Primary completion: phase 4 study in Pulmonary Arterial HypertensionNCT07600723
  3. Jun 16, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionNCT06925750
  4. Sep 21, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionNCT05587712

TargetBeta

INHBA →read by rule
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule

Other programs on INHBA

ProgramCompanyFurthest phaseStudies
garetosmabruleRegeneron Pharmaceuticalsphase 39

Studies

All 22 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07899905Hypertension, Pulmonary4Not yet recruitingMar 21, 202840
NCT07839585Hypertension, Pulmonary3Not yet recruitingJan 8, 2030352
NCT07646860Pulmonary Arterial Hypertension · Japan2RecruitingMay 24, 20296
NCT07600723Pulmonary Arterial Hypertension · India4RecruitingApr 3, 202830
NCT07218029Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3Active, not recruitingDec 7, 2028815
NCT06930664Healthy · United States1CompletedNov 11, 2025146
NCT06925750Pulmonary Arterial Hypertension · United States, Argentina, Australia and more2Active, not recruitingJun 16, 2028130
NCT06843460Healthy · China1CompletedMay 21, 202424
NCT06814145Hypertension, Pulmonary · United States, Belgium, Canada and more2Active, not recruitingAug 10, 2035440
NCT06664801Pulmonary Arterial Hypertension · United States, Argentina, Australia and more2CompletedNov 20, 2025164
NCT05818137Pulmonary Arterial Hypertension · Japan3CompletedMar 12, 202446
NCT05587712Pulmonary Arterial Hypertension · United States, Australia, Colombia and more2RecruitingSep 21, 202842
NCT04945460Hypertension, Pulmonary · United States, Belgium, Canada and more2CompletedSep 5, 2025165
NCT04896008Pulmonary Arterial Hypertension · United States, Australia, Belgium and more3CompletedJul 26, 2024173
NCT04811092Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3TerminatedApr 3, 2025321
NCT04576988Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedAug 26, 2022324
NCT03738150Pulmonary Arterial Hypertension · United States2CompletedDec 21, 202121
NCT03496207Pulmonary Arterial Hypertension · United States, Australia, Brazil and more2CompletedMar 9, 2022106
NCT01736683Anemia · United States, France2CompletedApr 30, 201874
NCT01284348Anemia2TerminatedSep 21, 201226
NCT01190644Solid Tumors · United States2TerminatedSep 18, 20125
NCT00931606Anemia · United States, Russian Federation2TerminatedNov 18, 201030

How it is read

Names in the registry

  • “Sotatercept”, 22 entries
  • “Sotatercept 0.3 mg/kg”, 1 entry
  • “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”, 1 entry
  • “Sotatercept Autoinjector”, 1 entry
  • “ACE-011”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.